DK0667901T4 - Hidtil ukendt cytokin - Google Patents

Hidtil ukendt cytokin

Info

Publication number
DK0667901T4
DK0667901T4 DK92925017T DK92925017T DK0667901T4 DK 0667901 T4 DK0667901 T4 DK 0667901T4 DK 92925017 T DK92925017 T DK 92925017T DK 92925017 T DK92925017 T DK 92925017T DK 0667901 T4 DK0667901 T4 DK 0667901T4
Authority
DK
Denmark
Prior art keywords
hitherto unknown
unknown cytokine
cytokine
hitherto
immunogen
Prior art date
Application number
DK92925017T
Other languages
English (en)
Other versions
DK0667901T3 (da
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Srinivasan Subhashini
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0667901(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0667901T3 publication Critical patent/DK0667901T3/da
Publication of DK0667901T4 publication Critical patent/DK0667901T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92925017T 1991-10-25 1992-10-23 Hidtil ukendt cytokin DK0667901T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (2)

Publication Number Publication Date
DK0667901T3 DK0667901T3 (da) 2004-12-27
DK0667901T4 true DK0667901T4 (da) 2008-11-10

Family

ID=27120174

Family Applications (3)

Application Number Title Priority Date Filing Date
DK98113461T DK0897983T3 (da) 1991-10-25 1992-10-23 Antistoffer mod CD40-L
DK92925017T DK0667901T4 (da) 1991-10-25 1992-10-23 Hidtil ukendt cytokin
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98113461T DK0897983T3 (da) 1991-10-25 1992-10-23 Antistoffer mod CD40-L

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf

Country Status (12)

Country Link
EP (2) EP0667901B2 (da)
JP (2) JP3308534B2 (da)
KR (1) KR100283541B1 (da)
AT (2) ATE239790T1 (da)
AU (1) AU661360B2 (da)
CA (2) CA2121798C (da)
DE (2) DE69233402T3 (da)
DK (3) DK0897983T3 (da)
ES (2) ES2198025T3 (da)
FI (2) FI116850B (da)
NO (2) NO317625B1 (da)
WO (1) WO1993008207A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0612529B1 (en) * 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
ATE256180T1 (de) * 1993-01-22 2003-12-15 Immunex Corp Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
WO1995006666A1 (en) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
ATE179616T1 (de) * 1993-09-02 1999-05-15 Dartmouth College Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
DK0763057T3 (da) 1994-04-28 2006-03-27 Boehringer Ingelheim Pharma Fremgangsmåde til proliferering og differentiering af B celler og anvendelse deraf
AU699291B2 (en) * 1995-03-01 1998-11-26 Immunex Corporation Method for stimulating an immune response
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
MX9709447A (es) * 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
JPH11508262A (ja) * 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
DE69728269T2 (de) * 1996-06-14 2005-03-10 University Of Washington, Seattle Absorbtionsverbessertes differentielles extraktionsverfahren
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP1076699B1 (en) 1998-05-14 2008-10-29 Immunex Corporation Method of inhibiting osteoclast activity
HK1042114B (zh) * 1998-10-23 2006-09-29 Amgen K-A, Inc. 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2003508016A (ja) * 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2002028905A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
US20050054565A1 (en) * 2001-07-31 2005-03-10 John Lucas Agonists and antagonists of moxifin for the treatment of metabolic disorders
WO2003035887A1 (en) 2001-09-20 2003-05-01 Immunex Corporation Selection of cells expressing heteromeric polypeptides
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
EP1594955B1 (en) 2003-02-14 2012-04-11 Biogen Idec MA Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US20080145931A1 (en) 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
BRPI0906490A2 (pt) 2008-01-15 2015-07-14 Abbott Lab Vetores de expressão de mamífero melhorados e uso dos mesmos
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
NO2525817T3 (da) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
BR112018073316A2 (pt) 2016-05-11 2019-06-04 Amgen Inc seleção direta de células que expressam altos níveis de proteínas heteroméricas usando vetores de complementação intragênica da glutamina sintetase
BR112019017713A2 (pt) * 2017-02-27 2020-04-07 Shattuck Labs Inc proteínas quiméricas à base de csf1r
CN118994414A (zh) 2017-02-27 2024-11-22 沙塔克实验室有限公司 基于tigit和light的嵌合蛋白
MX2021012471A (es) 2019-04-11 2022-01-04 Univ Arkansas Aptameros de adn especificos de cd40 como adyuvantes de vacunas.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
DK0822199T3 (da) 2004-12-27
NO320073B1 (no) 2005-10-17
FI116850B (fi) 2006-03-15
ATE274055T1 (de) 2004-09-15
NO317625B1 (no) 2004-11-29
CA2121798A1 (en) 1993-04-29
FI981765A0 (fi) 1998-08-17
FI941837L (fi) 1994-05-30
DK0667901T3 (da) 2004-12-27
FI981765L (fi) 1998-08-17
ES2198025T3 (es) 2004-01-16
DE69233402T2 (de) 2005-09-15
NO941422L (da) 1994-06-27
NO980030L (no) 1998-01-05
KR100283541B1 (ko) 2001-03-02
DE69233051D1 (de) 2003-06-12
EP0897983A3 (en) 1999-03-17
AU3122693A (en) 1993-05-21
ATE239790T1 (de) 2003-05-15
CA2312667C (en) 2002-11-19
EP0667901A4 (en) 1995-06-22
EP0897983B1 (en) 2003-05-07
EP0897983A2 (en) 1999-02-24
WO1993008207A1 (en) 1993-04-29
CA2121798C (en) 2007-07-24
CA2312667A1 (en) 1993-04-29
NO980030D0 (no) 1998-01-05
NO941422D0 (no) 1994-04-19
DE69233402D1 (de) 2004-09-23
JPH07504083A (ja) 1995-05-11
JP2877788B2 (ja) 1999-03-31
EP0667901B1 (en) 2004-08-18
JP3308534B2 (ja) 2002-07-29
EP0667901A1 (en) 1995-08-23
AU661360B2 (en) 1995-07-20
FI941837A0 (fi) 1994-04-20
FI116828B (fi) 2006-03-15
JPH10150994A (ja) 1998-06-09
ES2227513T5 (es) 2009-04-01
EP0667901B2 (en) 2008-10-15
HK1019343A1 (en) 2000-02-03
DE69233402T3 (de) 2009-06-25
DK0897983T3 (da) 2003-08-11
ES2227513T3 (es) 2005-04-01
DE69233051T2 (de) 2004-03-11

Similar Documents

Publication Publication Date Title
DK0667901T3 (da) Hidtil ukendt cytokin
DE3773293D1 (de) Weiche intraokulare linse.
FI892020A0 (fi) Fack foer is och iskuber formade i detta.
DE69009901D1 (de) Lichtleiter.
DE3685004D1 (de) Intraokulare linse.
DE3762798D1 (de) Intraokulare linse mit konvergierenden und divergierenden optischen teilen.
DE68923240D1 (de) Nichtabbildende Lichtquelle.
SE8403155L (sv) Sond med instellbart kontaktstift
DE68916079D1 (de) Intraokulare Linse.
DE68900533D1 (de) Optischer positionssensor.
FI912586A0 (fi) Adipsin och komplement d aktiviteter innehaollande kombinationsproteiner.
DE68924077D1 (de) Optisches Gerät mit Laser.
DE69007332D1 (de) Optische Verstärkungseinrichtung mit niedrigem Rauschen.
DE68917796D1 (de) Intraokulare Linse.
ATE103594T1 (de) Fucosidase-inhibitoren.
DE69022361D1 (de) Intraokulare Linse.
DE3784141D1 (de) Lichteinstellungseinrichtung.
DE69022808D1 (de) Komparator mit kontrolliertem Ausgang.
DK188689D0 (da) Linse
DE3768771D1 (de) Faltbare intraokulare linse.
ATE98761T1 (de) Laermisolierung mit lichtreflektierender oberflaeche.
ES1006699Y (es) Quemador protesico orientable.
NO910287D0 (no) Flerfokal intraokulaer linse.
NO882944L (no) Intraokulaer linse med justerbar styrke.
DE69128032D1 (de) Automatische Einstellung der optischen Ausgangsleistung von mehreren optischen Sendern